Elevance Health Inc.

(New York Stock Exchange)
Back to all articles
Somewhat Bullish +45

Elevance Health (ELV) Stock Looks Reasonable After Raised Earnings Outlook

Earnings report Financial outlook AI-generated analysis

πŸ“ˆ Elevance Health shares have gained 33.6% over the past 12 months, raising questions about whether current earnings fully support the price advance.

πŸ“‰ The company trades at a P/E ratio of approximately 18.1x, which is well below the broader Healthcare sector average of 25.3x and peer group averages near 31.4x.

πŸ’° Management has lifted its longer-term earnings outlook and flagged potential improvements in Medicaid margins to support future profit growth.

πŸ›‘οΈ Carelon's complex behavioral care programs have shown around 10% cost savings and reduced inpatient admissions, supporting value-based relationships.

πŸ₯ Expansion of home-based CareBridge services into new markets aims to deepen revenue from health services and support margin resilience.

⚠️ Persistent elevated utilization in behavioral health, specialty pharmacy, and emergency departments suggests cost savings may not scale fast enough across the wider book.

πŸ“Š Analyst consensus narratives on Simply Wall St currently split between a bullish view of 9% undervaluation and a bearish view of roughly fair value.

βš–οΈ Despite a recent lawsuit over alleged fraudulent billing, the market continues to price Elevance Health at a discount to sector norms.

Bullish Signals
  • Management has lifted its longer-term earnings outlook, signaling confidence in future profit growth and operational efficiency.
  • The stock trades at a P/E ratio of approximately 18.1x, which is significantly lower than the broader Healthcare sector average of 25.3x and peer group averages near 31.4x, suggesting potential undervaluation.
  • Carelon's behavioral care programs have demonstrated around 10% cost savings and reduced inpatient admissions, indicating strong operational performance.
  • Expansion of home-based CareBridge services into new markets is expected to deepen value-based relationships and support future margin resilience.
Risk Factors
  • Persistent elevated utilization in behavioral health, specialty pharmacy, and emergency departments suggests that projected medical cost savings may not scale fast enough across the wider book.
  • A recent lawsuit over alleged fraudulent billing has put a spotlight on the company's risk controls, though the market currently prices the shares at a discount to sector norms.
Full Analysis
Elevance Health (ELV) shares have appreciated 33.6% over the past year, prompting investors to assess whether current earnings power justifies the valuation. The company recently raised its longer-term earnings outlook and highlighted potential improvements in Medicaid margins, which could enhance the durability and predictability of future profit growth within an earnings-based valuation framework. Analysts covering Elevance Health are currently divided on the stock's fair value. Simply Wall St analysis suggests a bullish case where the stock is 9% undervalued, driven by expansion in Carelon's behavioral care programs that have demonstrated approximately 10% cost savings and reduced inpatient admissions. These initiatives aim to deepen value-based relationships and support margin resilience. Conversely, a bearish perspective views Elevance Health as roughly fairly valued, citing concerns that persistent elevated utilization in behavioral health, specialty pharmacy, and emergency departments may prevent the projected medical cost savings from scaling effectively across the wider book of business. Despite these mixed analyst views, the stock trades at approximately 18.1x earnings, which is significantly lower than the broader Healthcare sector average of 25.3x and peer group averages near 31.4x.